‘0015 Update: Path Clarifies; ‘4001 Next Catalyst

研报英文原文证据摘录

‘0015 Update: Path Clarifies; ‘4001 Next Catalyst

nal development. That said,

execution remains dependent on regulatory alignment and timely trial initiation,

particularly as the first NSCLC study is expected to begin within a similar window as

upcoming data updates. Taken together, the outlined path is defined and funded, but

we acknowledge still requires continued regulatory clarity and operational execution.

IP overhang persists, with a data-dependent path to mitigation. On IP, we

continue to see a credible path for the current valuation discount to diminish if

clinical differentiation is sustained, though we do not view the risk as resolved at

this stage (see our published analysis assessing the patent infringement risk here).

Revolution Medicines' (RVMD, not covered) claim relies on the Doctrine of

Equivalents rather than literal infringement, and our prior analysis suggests limited

precedent for successful claims under this framework, albeit with small sample

sizes. More importantly, sustained differentiation across dose, PK/PD, efficacy,

safety, dose intensity, and combinability could increasingly support arguments

around function-way-result and insubstantial differences. That said, this will require

a more mature and clearly differentiated clinical profile over time. Overall, we

believe continued strengthening of ’0015’s efficacy and safety profile could position

the program to largely mitigate the IP overhang over time, though additional data

will be required to confirm this trajectory.

Balanced risk-reward, with a defined path to a more constructive stance. While

risks remain, including small sample sizes at 32mg in PDAC, immature durability,

evolving combination data, and dependence on regulatory alignment and trial